Related Experiment Video
Updated: Jul 10, 2026

Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
Published on: March 17, 2023
Examination of microbiological quality of pharmaceutical raw materials
L Bomblies1, C Weiss, G Beckmann
1lothar.bomblies@labor-ls.de
Abstract:
With the ICH harmonisation of the chapters 'Microbiological examination of non-sterile products: microbial enumeration tests' 'Test for specified micro-organisms' and 'Microbiological quality of pharmaceutical preparations' between Ph. Eur., USP and JP, altered specifications and test methods for pharmaceutical preparations are applicable in Europe since 2007 From this results the necessity to check and, where appropriate, adapt microbiological limit values in the individual monographs of the Ph. Eur.- provided that they contain such values. The present examination, which gives an evaluation of 3387 examinations in the period from 1997 to 2006 of the microbiological quality of 40 different pharmaceutical raw materials, is to provide a database for this purpose. It was shown that the existing limit values were not exceeded for 93% of the examined raw materials. 5.5% of the examinations were within the specification after using the valid tolerance factor of 5 of the old methods. Only 1.5% of all examinations led to OOS results. In comparison an evaluation of these data against the new, harmonised limits is leading to an increase in OOS results to a total of 6%. Most raw materials were of the required microbiological quality but a few, predominantly of plant origin, exceeded the limits. Regular incoming goods inspections are indispensable here.
Insights
Harmonized European Pharmacopoeia (Ph. Eur.) standards impact pharmaceutical quality. While most raw materials meet standards, new limits reveal some plant-derived materials exceed specifications, necessitating regular inspections.
Area of Science:
- Pharmaceutical Microbiology
- Regulatory Science
Background:
- International Council for Harmonisation (ICH) has harmonized microbiological testing methods across major pharmacopoeias (Ph. Eur., USP, JP).
- New harmonized standards became effective in Europe in 2007, necessitating a review of existing microbiological limits in Ph. Eur. monographs.
Purpose of the Study:
- To evaluate the microbiological quality of pharmaceutical raw materials based on historical data (1997-2006).
- To provide a database for adapting Ph. Eur. microbiological limit values in light of harmonized standards.
- To compare compliance rates using old versus new harmonized microbiological limits.
Main Methods:
- Analysis of 3387 microbiological examinations from 40 different pharmaceutical raw materials.
- Evaluation of data against existing Ph. Eur. limits and newly harmonized limits.
- Assessment of out-of-specification (OOS) results under both regulatory frameworks.
Main Results:
- 93% of raw materials met existing microbiological limits.
- Under old methods, 5.5% of results were within specification using a tolerance factor of 5, with only 1.5% OOS.
- Applying new harmonized limits increased OOS results to 6%, primarily for plant-derived raw materials.
Conclusions:
- Most pharmaceutical raw materials possess adequate microbiological quality.
- A small percentage of raw materials, particularly those of plant origin, exceed the newly harmonized microbiological limits.
- Regular incoming goods inspections are crucial for ensuring pharmaceutical raw material quality.
Related Concept Videos
Good Manufacturing Practices
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
Clinically Relevant Drug Product Specifications: Methods of Establishment
Rapid Identification of Pathogens
Automated Microbial Diagnostics
Need for Obtaining Pure Cultures

